WO2023018400A1 - Product containing potent extracellular vesicles and metabolites from an inhaler convalescent patient plasma in the treatment of covid-19 pneumonia - Google Patents
Product containing potent extracellular vesicles and metabolites from an inhaler convalescent patient plasma in the treatment of covid-19 pneumonia Download PDFInfo
- Publication number
- WO2023018400A1 WO2023018400A1 PCT/TR2022/050841 TR2022050841W WO2023018400A1 WO 2023018400 A1 WO2023018400 A1 WO 2023018400A1 TR 2022050841 W TR2022050841 W TR 2022050841W WO 2023018400 A1 WO2023018400 A1 WO 2023018400A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- covid
- treatment
- pneumonia
- composition according
- plasma
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 18
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 7
- 239000002207 metabolite Substances 0.000 title description 3
- 230000003389 potentiating effect Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 239000013543 active substance Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 4
- 206010001053 acute respiratory failure Diseases 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000005077 saccule Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
Definitions
- the invention is related to a composition
- a composition comprising the immune plasma extracellular vesicles developed against the COVID-19 viral infection and metabolites which are the cellular elements, vitamins, minerals, fatty acids, nucleic acids, DNA and RNA fragments, proteins, and/or enzymes.
- COVID-19 SARS-CoV-2
- SARS-CoV-2 which is known to be a viral respiratory tract illness that emerged first in the Wuhan province of China, belongs to the coronavirus family which was witnessed before with SARS and MERS, infecting through droplets. Fever, cough, and malaise were considered as the most prominent symptoms of COVID-19, which took a hold of the world.
- the main object of the invention is to obtain a pharmaceutical composition with high biocompatibility that does not contain toxic substances that will harm cells and tissues.
- the object of the invention is to prepare a pharmaceutical composition that is more effective, easily applicable, and affordable than the readily available medications for both preventing the COVID-19 virus infection and decreasing cellular inflammation.
- Another object of the invention is to remedy the cellular and tissular damage in the damaged organs, alleviate the damage-induced inflammation (burning), eliminate the virus- and inflammation-induced vasocontraction, and provide tissue hemostasis.
- Another object of the invention is to prepare a composition to be used in the preparation of the medication to be used in the treatment of patients with CO VID-19 characterized by severe acute respiratory failure (pneumonia).
- Figure 1 Extracellular vesicle characterization. Electron microscope image showing morphological features and size measurements of the immune plasma exosomes.
- the invention is related to a pharmaceutical composition that comprises a therapeutically effective amount of extracellular vesicle obtained from the immune plasma of a patient who had suffered from COVID-19 and recovered as the active substance, and at least one pharmaceutically acceptable excipient.
- Extracellular vesicles are the saccules synthesized by cells that are used as ‘cell free’ therapy without cells. They play a role in repairing the damage that occurs in the cells, tissues, organs, or organisms or inter-cellular communication. In the convalescent plasma, the body’s immune response against the pathogen and a protective co-factor are present. The advantage of using EVs and not just the plasma is to get rid of cellular waste and other useless components in the plasma. The exosome goes directly to the damaged area and enters the cell, both preventing the entry of the virus into the cell, and taking part in repair mechanisms.
- the convalescent plasma is the immune plasma of the patient who had suffered from COVID-19 and recovered.
- the composition of the invention is used for the treatment of patients with COVID-19 characterized by severe acute respiratory failure (pneumonia).
- the composition of the invention comprises a therapeutically effective amount of extracellular vesicle and at least one pharmaceutically acceptable excipient.
- the pharmaceutically acceptable excipient may be PEG (polyethylene glycol), DEX (Dextran), sucrose.
- the effective amount is 107-1012 particles in 0,l-20mL saline per application.
- the composition of the invention is administered by inhalation or topically and contains dextran as an excipient.
- the exosome is isolated from the blood plasma obtained from the patient who had suffered from Covid- 19 and whose antibody test came as positive.
- isolation is performed with the isolation method with a double-phase liquid system.
- the prepared plasma is mixed with the isolation solution in 50mL falcons by inverting 20 times at a ratio of 1 : 1 and centrifuged at 1,000 x g for 10 minutes to achieve phase separation.
- the upper phase which corresponds to approximately 90% of the total volume is discarded and the lower phase, where small extracellular vesicles are accumulated is collected and stored at -80 degrees until use.
- the isolated extracellular vesicles are observed as spherical and in the size range of 50-200 nm, as they should be.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention is related to a pharmaceutical composition comprising an extracellular vesicle obtained from convalescent plasma as the active substance to be used in the treatment of pneumonia caused by COVID-19. In the invention, the convalescent plasma is the immune plasma of a patient who had suffered from COVID-19 and recovered. The composition of the invention comprises a therapeutically effective amount of extracellular vesicle and at least one pharmaceutically acceptable excipient.
Description
PRODUCT CONTAINING POTENT EXTRACELLULAR VESICLES AND METABOLITES FROM AN INHALER CONVALESCENT PATIENT PLASMA IN THE TREATMENT OF COVID-19 PNEUMONIA
Technical Field
The invention is related to a composition comprising the immune plasma extracellular vesicles developed against the COVID-19 viral infection and metabolites which are the cellular elements, vitamins, minerals, fatty acids, nucleic acids, DNA and RNA fragments, proteins, and/or enzymes.
State of Art (Prior Art)
COVID-19 (SARS-CoV-2), which is known to be a viral respiratory tract illness that emerged first in the Wuhan province of China, belongs to the coronavirus family which was witnessed before with SARS and MERS, infecting through droplets. Fever, cough, and malaise were considered as the most prominent symptoms of COVID-19, which took a hold of the world. Several medication studies were made to cure Covid- 19. However, the said medications have been found to be insufficient in treating the disease and preventing the infection of the virus. In addition, the medications that are used create cellular and tissular toxicity with low biocompatibility. Besides, they cause high production costs.
Brief Description and Objects of the Invention
The main object of the invention is to obtain a pharmaceutical composition with high biocompatibility that does not contain toxic substances that will harm cells and tissues.
The object of the invention is to prepare a pharmaceutical composition that is more effective, easily applicable, and affordable than the readily available medications for both preventing the COVID-19 virus infection and decreasing cellular inflammation.
Another object of the invention is to remedy the cellular and tissular damage in the damaged
organs, alleviate the damage-induced inflammation (burning), eliminate the virus- and inflammation-induced vasocontraction, and provide tissue hemostasis.
Another object of the invention is to prepare a composition to be used in the preparation of the medication to be used in the treatment of patients with CO VID-19 characterized by severe acute respiratory failure (pneumonia).
Description of the Figures Describing the Invention
Figure 1: Extracellular vesicle characterization. Electron microscope image showing morphological features and size measurements of the immune plasma exosomes.
Detailed Description of the Invention
The invention is related to a pharmaceutical composition that comprises a therapeutically effective amount of extracellular vesicle obtained from the immune plasma of a patient who had suffered from COVID-19 and recovered as the active substance, and at least one pharmaceutically acceptable excipient.
Extracellular vesicles (EVs) are the saccules synthesized by cells that are used as ‘cell free’ therapy without cells. They play a role in repairing the damage that occurs in the cells, tissues, organs, or organisms or inter-cellular communication. In the convalescent plasma, the body’s immune response against the pathogen and a protective co-factor are present. The advantage of using EVs and not just the plasma is to get rid of cellular waste and other useless components in the plasma. The exosome goes directly to the damaged area and enters the cell, both preventing the entry of the virus into the cell, and taking part in repair mechanisms.
In the invention, the convalescent plasma is the immune plasma of the patient who had suffered from COVID-19 and recovered. The composition of the invention is used for the treatment of patients with COVID-19 characterized by severe acute respiratory failure (pneumonia). The composition of the invention comprises a therapeutically effective amount of extracellular vesicle and at least one pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may be PEG (polyethylene glycol), DEX (Dextran), sucrose. Here, the effective amount is 107-1012 particles in 0,l-20mL saline per application.
The composition of the invention is administered by inhalation or topically and contains dextran as an excipient.
The exosome is isolated from the blood plasma obtained from the patient who had suffered from Covid- 19 and whose antibody test came as positive. For the isolation of immune plasma exosomes used within the scope of the invention, isolation is performed with the isolation method with a double-phase liquid system.
Extracellular Vesicle Isolation:
The prepared plasma is mixed with the isolation solution in 50mL falcons by inverting 20 times at a ratio of 1 : 1 and centrifuged at 1,000 x g for 10 minutes to achieve phase separation. The upper phase, which corresponds to approximately 90% of the total volume is discarded and the lower phase, where small extracellular vesicles are accumulated is collected and stored at -80 degrees until use.
As seen in Figure 1, the isolated extracellular vesicles are observed as spherical and in the size range of 50-200 nm, as they should be.
As a result of the analysis performed by determining the protein content of the extracellular vesicles obtained from convalescent immune plasmas, and as a result of the analysis performed using the ontology program of the KEGG gene bank, 64 proteins related to COVID-19 were detected in these extracellular vesicles and these proteins act against the COVID-19 virus and inflammation in the body in the immune system.
Table 1. List of proteins that are present in the exosomes obtained from the convalescent immune plasma as a result of the analysis performed with the KEGG Ontology data bank and that are related to “Coronavirus disease - COVID-19”
Claims
CLAIMS A pharmaceutical composition, characterized in that; it comprises a therapeutically effective amount of extracellular vesicle obtained from the immune plasma of a patient who had suffered from COVID-19 and recovered as the active substance, and at least one pharmaceutically acceptable excipient. A composition according to Claim 1, characterized in that; the therapeutically effective amount of extracellular vesicle is 107-1012 particles in 0,l-20mL saline per application. A composition according to Claim 1 or 2, characterized in that; it is administered by inhalation or topically. A composition according to Claim 1, characterized in that; the pharmaceutically acceptable excipient is PEG, dextran, gelatin, alginate, or sucrose. A composition according to Claim 1, characterized in that; the extracellular vesicle size is in the range of 50-200 nm. A composition according to any one of the above claims, characterized in that; it is used in the treatment of patients with COVID-19 characterized by severe acute respiratory failure (pneumonia). A medicine, characterized in that; it comprises the composition according to any one of Claims 1-5. A medicine according to Claim 7, characterized in that; it is used in the treatment of patients with COVID-19 characterized by severe acute respiratory failure (pneumonia).
6
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2021050793 | 2021-08-11 | ||
| TRPCT/TR2021/050793 | 2021-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023018400A1 true WO2023018400A1 (en) | 2023-02-16 |
Family
ID=85200863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2022/050841 WO2023018400A1 (en) | 2021-08-11 | 2022-08-11 | Product containing potent extracellular vesicles and metabolites from an inhaler convalescent patient plasma in the treatment of covid-19 pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023018400A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346108A (en) * | 2020-04-28 | 2020-06-30 | 国药集团武汉血液制品有限公司 | Preparation method of virus inactivated plasma for treating COVID-19 |
-
2022
- 2022-08-11 WO PCT/TR2022/050841 patent/WO2023018400A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346108A (en) * | 2020-04-28 | 2020-06-30 | 国药集团武汉血液制品有限公司 | Preparation method of virus inactivated plasma for treating COVID-19 |
Non-Patent Citations (2)
| Title |
|---|
| ANAND KRISHNAN, VADIVALAGAN CHITHRAVEL, JOSEPH JITCY SAJI, SINGH SACHIN KUMAR, GULATI MONICA, SHAHBAAZ MOHD, ABDELLATTIF MAGDA H.,: "A novel nano therapeutic using convalescent plasma derived exosomal (CPExo) for COVID-19: A combined hyperactive immune modulation and diagnostics", CHEMICO-BIOLOGICAL INTERACTIONS., ELSEVIER SCIENCE IRLAND., IR, vol. 344, 1 August 2021 (2021-08-01), IR , pages 109497, XP093035757, ISSN: 0009-2797, DOI: 10.1016/j.cbi.2021.109497 * |
| M. HASSANPOUR ET AL.: "The role of extracellular vesicles in COVID-19 virus infection", INFECT. GENET. EVOL. J. MOL. EPIDEMIOL. EVOL. GENET. INFECT. DIS., vol. 85, no. 104422, 2020, XP086352654, DOI: 10.1016/j.meegid.2020.104422 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3111947B1 (en) | Periplaneta americana extract or periplaneta americana medicinal powder as well as preparation method thereof and application in preparation of a medicament used for preventing and treating radiation-induced damages | |
| WO2021203614A1 (en) | Pharmaceutical composition for treatment of coronavirus diseases and preparation method therefor and application thereof | |
| WO2024027673A1 (en) | Use of nocardia rubra cell wall skeleton in treatment of chronic cervicitis | |
| CN113244212A (en) | Application of baicalein in preparation of medicine for preventing and/or treating novel coronavirus infection diseases | |
| CN113521101A (en) | Application of exosome derived from stem cells in preparation of medicine for treating chronic obstructive pulmonary disease | |
| CN101095691A (en) | Application of phillyrin in the preparing of medicine for treating or preventing acute and chronic liver injury and hepar fibrosis | |
| CN114712453A (en) | Application of Chinese medicinal composition in preparing medicine for resisting virus, protecting viscera and enhancing immunity | |
| WO2023018400A1 (en) | Product containing potent extracellular vesicles and metabolites from an inhaler convalescent patient plasma in the treatment of covid-19 pneumonia | |
| NL2032676B1 (en) | Neutral oligosaccharide cordyceps militaris for regulating lung lymphocyte differentiation, preparation method and applications thereof | |
| WO2023115789A1 (en) | New generation synthetic pulmonary surfactant formulation and clinical use thereof | |
| Guan et al. | A novel strategy against hepatitis B virus: Glycyrrhetnic acid conjugated multi-component synergistic nano-drug delivery system for targeted therapy | |
| JP2022536582A (en) | Use of an extract from rabbit skin inflamed by vaccinia virus in the treatment of hematopoietic injury | |
| WO2013023443A1 (en) | Pharmaceutical application of peptide of soft-shell turtle | |
| CN100594930C (en) | Medicinal composition using anterior pituitary adrenal cortical extract as main component, and its preparation method and use | |
| WO2022134257A1 (en) | Use of compound xueshuantong capsule in preparation of drug for improving microcirculation | |
| CN113476497B (en) | Prunella vulgaris extract with HSV (herpes Simplex Virus) resisting activity as well as preparation method and medical application thereof | |
| TWI847112B (en) | Use of nocardia rubra cell wall skeleton in the treatment of radiation related disease | |
| CN110721193B (en) | Application of cynomorium songaricum total polysaccharide in preparation of medicine for treating asthma | |
| CN112891482B (en) | A composition for treating coronavirus infection | |
| CN117224518B (en) | Application of sofalcone in preparation of medicine for preventing/treating allergic asthma | |
| CN108210457B (en) | Medicinal application of collagen peptide, cucurbitacin oral micelle and preparation method thereof | |
| CN111214495B (en) | Application of mycobacterium vaccae for injection in preparation of medicine for preventing and treating respiratory system RSV infection | |
| EA025133B1 (en) | Method for producing dry extracts | |
| CN107028887A (en) | Liposome is used for the purposes for treating chronic viral hepatitis type B | |
| CN109771486B (en) | Chinese medicinal compound preparation for treating infantile viral myocarditis and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22856350 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |